In order to overcome these limitations, NMR data about FGF2/PTX3 interaction and pharmacophore modeling of a minimal PTX3-derived FGF2-binding pentapeptide were used for the identification of NSC12 as the first small molecule able to act as an extracellular pan-FGF trap and endowed with a significant activity against various FGF-dependent tumor types (17, 36). This evidence concerns the gene FGF2 and neoplasm.